In a translational context, while MCM3 expression appears to be a stronger prognostic biomarker than RBM3, not least in thin melanomas, the inverse correlation between tumour-specific expression of MCM3 and RBM3, which is in line with previous observations in ovarian cancer [16], may give some directions towards further functional studies of the role and interaction of these proteins in melanoma progression and metastasis. This evidence concerns the gene RBM3 and neoplasm.